Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 5/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | USP1 | O94782 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31692747 | 0.81 | GPR119 (0.42) | GPR119 | |
| SCHEMBL31692690 | 0.76 | MAPK1 (0.39) | NAMPTGPR119HDAC1HDAC2 | |
| SCHEMBL31496087 | 0.74 | CREBBP (0.63) | CREBBPBRD4 | |
| SCHEMBL30329049 | 0.74 | GPR119 (0.48) | MGLLGPR119 | |
| SCHEMBL31496189 | 0.73 | TBK1 (0.43) | GPR119CREBBPBRD4TBK1 | |
| SCHEMBL25198716 | 0.73 | CREBBP (0.41) | CREBBPBRD4 | |
| SCHEMBL30395478 | 0.73 | CREBBP (0.41) | CREBBPBRD4 | |
| SCHEMBL20396131 | 0.72 | MGLL (0.46) | MGLLNAMPTGPR119TBK1KDM1A | |
| SCHEMBL31496147 | 0.72 | DGAT1 (0.56) | MGLLNAMPTGPR119 | |
| SCHEMBL25193494 | 0.71 | PDK4 (0.47) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136578-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025081092-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136578-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | AR, SHBG, FSHR | MGLL 3789/4885NAMPT 3920/4885GPR119 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.